US8415459B2 - Antibody to GDF8 and uses thereof - Google Patents

Antibody to GDF8 and uses thereof Download PDF

Info

Publication number
US8415459B2
US8415459B2 US12/262,712 US26271208A US8415459B2 US 8415459 B2 US8415459 B2 US 8415459B2 US 26271208 A US26271208 A US 26271208A US 8415459 B2 US8415459 B2 US 8415459B2
Authority
US
United States
Prior art keywords
gdf8
antibody
seq
gdf
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/262,712
Other languages
English (en)
Other versions
US20090148436A1 (en
Inventor
Edward Roland LaVallie
Lisa Anne Collins-Racie
Christopher John Corcoran
Lioudmila Gennadievna Tchistiakova
John Adam Nowak
Riyez Karim
Xiang-Yang Tan
Kimberly Ann Marquette
Geertruida Machteld Veldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US12/262,712 priority Critical patent/US8415459B2/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TCHISTIAKOVA, LIOUDMILA GENNADIEVNA, COLLINS-RACIE, LISA ANNE, CORCORAN, CHRISTOPHER JOHN, KARIM, RIYEZ, LAVALLIE, EDWARD ROLAND, MARQUETTE, KIMBERLY ANN, TAN, XIANG-YANG, VELDMAN, GEERTRUIDA MACHTELD, NOWAK, JOHN ADAM
Publication of US20090148436A1 publication Critical patent/US20090148436A1/en
Assigned to WYETH LLC reassignment WYETH LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: WYETH
Priority to US13/791,700 priority patent/US9409981B2/en
Application granted granted Critical
Publication of US8415459B2 publication Critical patent/US8415459B2/en
Priority to US15/230,430 priority patent/US9850301B2/en
Priority to US15/844,526 priority patent/US10189896B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
US12/262,712 2007-11-01 2008-10-31 Antibody to GDF8 and uses thereof Expired - Fee Related US8415459B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/262,712 US8415459B2 (en) 2007-11-01 2008-10-31 Antibody to GDF8 and uses thereof
US13/791,700 US9409981B2 (en) 2007-11-01 2013-03-08 Antibody to GDF8 and uses thereof
US15/230,430 US9850301B2 (en) 2007-11-01 2016-08-07 Antibody to GDF8 and uses thereof
US15/844,526 US10189896B2 (en) 2007-11-01 2017-12-16 Antibody to GDF8 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US178307P 2007-11-01 2007-11-01
US12/262,712 US8415459B2 (en) 2007-11-01 2008-10-31 Antibody to GDF8 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/791,700 Division US9409981B2 (en) 2007-11-01 2013-03-08 Antibody to GDF8 and uses thereof

Publications (2)

Publication Number Publication Date
US20090148436A1 US20090148436A1 (en) 2009-06-11
US8415459B2 true US8415459B2 (en) 2013-04-09

Family

ID=40303702

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/262,712 Expired - Fee Related US8415459B2 (en) 2007-11-01 2008-10-31 Antibody to GDF8 and uses thereof
US13/791,700 Expired - Fee Related US9409981B2 (en) 2007-11-01 2013-03-08 Antibody to GDF8 and uses thereof
US15/230,430 Expired - Fee Related US9850301B2 (en) 2007-11-01 2016-08-07 Antibody to GDF8 and uses thereof
US15/844,526 Expired - Fee Related US10189896B2 (en) 2007-11-01 2017-12-16 Antibody to GDF8 and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/791,700 Expired - Fee Related US9409981B2 (en) 2007-11-01 2013-03-08 Antibody to GDF8 and uses thereof
US15/230,430 Expired - Fee Related US9850301B2 (en) 2007-11-01 2016-08-07 Antibody to GDF8 and uses thereof
US15/844,526 Expired - Fee Related US10189896B2 (en) 2007-11-01 2017-12-16 Antibody to GDF8 and uses thereof

Country Status (19)

Country Link
US (4) US8415459B2 (ja)
EP (2) EP2215118B1 (ja)
JP (1) JP5756291B2 (ja)
KR (1) KR20100074321A (ja)
CN (1) CN101970487A (ja)
AR (1) AR069157A1 (ja)
AU (1) AU2008319265A1 (ja)
CA (1) CA2704315C (ja)
CO (1) CO6270358A2 (ja)
ES (1) ES2514518T3 (ja)
IL (1) IL205448A0 (ja)
MX (1) MX2010004915A (ja)
PA (1) PA8802601A1 (ja)
PE (1) PE20091163A1 (ja)
RU (1) RU2447084C2 (ja)
SA (1) SA08290697B1 (ja)
TW (1) TW200934510A (ja)
WO (1) WO2009058346A1 (ja)
ZA (1) ZA201003876B (ja)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017221145A1 (en) 2016-06-21 2017-12-28 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
US10189896B2 (en) * 2007-11-01 2019-01-29 Pfizer Inc. Antibody to GDF8 and uses thereof
WO2019169283A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
EP3677278A1 (en) 2018-07-11 2020-07-08 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
WO2020261178A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US11655291B2 (en) 2011-11-14 2023-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) * 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
ES2415666T3 (es) * 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2484372A1 (en) * 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
WO2009158025A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US8138142B2 (en) * 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
KR20140092941A (ko) * 2009-06-26 2014-07-25 아틀라스 안티바디스 에이비 면역검출능의 개선
CN102781518A (zh) * 2009-09-09 2012-11-14 阿塞勒隆制药公司 Actriib拮抗剂及其给药和用途
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8512950B2 (en) 2010-07-21 2013-08-20 Saint Louis University Biolayer interferometry measurement of biological targets
EP2606066A1 (en) * 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
TWI641687B (zh) * 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2861617A1 (en) * 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
MX2017006521A (es) * 2014-11-24 2017-08-09 Somalogic Inc Compuestos de acido nucleico para unirse al factor de diferenciacion de crecimiento 11.
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
WO2016120652A1 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle differentiation
WO2016120647A2 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle regeneration
SG11201708351XA (en) 2015-04-22 2017-11-29 Alivegen Usa Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
AU2016352967A1 (en) 2015-11-10 2018-06-21 Medimmune, Llc Binding molecules specific for ASCT2 and uses thereof
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
PT3368069T (pt) 2016-06-13 2020-11-11 Scholar Rock Inc Uso de inibidores da miostatina e terapias de combinação
MY193497A (en) * 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
JP2022543658A (ja) 2019-08-07 2022-10-13 アクアラン セラピューティクス コーポレーション 抗ｎａｍｐｔ抗体及びその用途
WO2022261480A1 (en) * 2021-06-11 2022-12-15 The Regents Of The University Of California Heparan sulfate mimetics to improve glucose clearance
CN114181908B (zh) * 2021-07-23 2023-11-17 无锡傲锐东源生物科技有限公司 抗人s100b蛋白鼠单克隆抗体及其应用
WO2023168326A2 (en) * 2022-03-03 2023-09-07 The Brigham And Women´S Hospital, Inc. Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
US11802870B1 (en) * 2022-12-13 2023-10-31 Panazee Kinetic immunoassay systems and methods

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034015A1 (en) 1995-04-24 1996-10-31 Boehringer Ingelheim Pharmaceuticals, Inc. Modified anti-icam-1 antibodies and their use in the treatment of inflammation
WO1997010847A1 (en) 1995-09-21 1997-03-27 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US6012454A (en) 1989-04-28 2000-01-11 Minnesota Mining And Manufacturing Company Dry powder inhalation device
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US6102035A (en) 1995-08-10 2000-08-15 Astra Aktiebolag Inhaler
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2003014161A2 (en) 2001-08-10 2003-02-20 Aberdeen University Antigen binding domains from fish
WO2003027248A2 (en) 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof
US20030118592A1 (en) 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030162714A1 (en) 2002-02-21 2003-08-28 Wyeth GASP1: a follistatin domain containing protein
US20030180306A1 (en) 2002-02-21 2003-09-25 Wyeth Follistatin domain containing proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040077053A1 (en) 1997-08-01 2004-04-22 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) receptors
US20040142382A1 (en) 2002-10-22 2004-07-22 Veldman Geertruida M. Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20050136049A1 (en) 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
US20060240488A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
US20060240487A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
WO2006116269A2 (en) 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
WO2007024535A2 (en) 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
WO2007047112A2 (en) 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies
WO2008030706A2 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251721T3 (es) * 1994-07-08 2006-05-01 The Johns Hopkins University School Of Medicine Factor-11 de diferenciacion del crecimiento.
US5562332A (en) 1994-12-27 1996-10-08 Hss Industries, Inc. Lobby table for lockable boxes with handicapped shelf
KR100582967B1 (ko) 2000-09-13 2006-05-24 엔테그리스, 아이엔씨. 액체 여과 기기
EP1635870A2 (en) 2003-06-02 2006-03-22 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
CN1934266A (zh) * 2004-03-23 2007-03-21 伊莱利利公司 抗肌肉生长抑素抗体
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound

Patent Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US6012454A (en) 1989-04-28 2000-01-11 Minnesota Mining And Manufacturing Company Dry powder inhalation device
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1996034015A1 (en) 1995-04-24 1996-10-31 Boehringer Ingelheim Pharmaceuticals, Inc. Modified anti-icam-1 antibodies and their use in the treatment of inflammation
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6102035A (en) 1995-08-10 2000-08-15 Astra Aktiebolag Inhaler
WO1997010847A1 (en) 1995-09-21 1997-03-27 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20040077053A1 (en) 1997-08-01 2004-04-22 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) receptors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US20030118592A1 (en) 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050202012A1 (en) 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunogloubulin fusion proteins
US20050202028A1 (en) 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050202534A1 (en) 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050238646A1 (en) 2001-01-17 2005-10-27 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050180970A1 (en) 2001-01-17 2005-08-18 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050202023A1 (en) 2001-01-17 2005-09-15 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050186216A1 (en) 2001-01-17 2005-08-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050136049A1 (en) 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
US20050175614A1 (en) 2001-01-17 2005-08-11 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2003014161A2 (en) 2001-08-10 2003-02-20 Aberdeen University Antigen binding domains from fish
WO2003027248A2 (en) 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US20030180306A1 (en) 2002-02-21 2003-09-25 Wyeth Follistatin domain containing proteins
US20030162714A1 (en) 2002-02-21 2003-08-28 Wyeth GASP1: a follistatin domain containing protein
US20040142382A1 (en) 2002-10-22 2004-07-22 Veldman Geertruida M. Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005094446A2 (en) 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
US20060240487A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
US20060240488A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
WO2006116269A2 (en) 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
WO2007024535A2 (en) 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
US20070087000A1 (en) 2005-08-19 2007-04-19 Walsh Frank S Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US7888486B2 (en) * 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
WO2007047112A2 (en) 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies
WO2008030706A2 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies

Non-Patent Citations (119)

* Cited by examiner, † Cited by third party
Title
Alfarano, C. et al., "The Biomolecular Interaction Network Database and related tools 2005 update," 2005, Nuc. Acids Res. Database Issue, vol. 33, pp. D418-D424.
Al-Lazikani, Bissan et al., "Standard Conformations for the Canonical Structures of Immunoglobulins," 1997, Journal of Molecular Biology, vol. 273, pp. 927-948.
Altschul, Stephen F. et al., "Basic Local Alignment Search Tool," 1990, Journal of Molecular Biology, vol. 215, pp. 403-410.
Angal, S. et al., A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody, 1993, Molecular Immunology, vol. 30, pp. 105-108.
Animal Cell Culture (R. I. Freshney ed. 1986).
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988.
Antibodies: A Laboratory Manual, eds. Harlow et al., Cold Spring Harbor Laboratory, 1988.
Antibody Engineering, 2nd ed., ed. Borrebaeck, Oxford University Press, 1995.
Arts et al. (2003)., vol. 13, pp. 2325-2332.
Ashmore, C. R. et al., "Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and "Double-Muscled" Cattle," 1974, Growth, vol. 38, pp. 501-507.
Ausubel et al., eds., Current Protocols in Molecular Biology, Sects. 2.10 & 6.3-6.4, John Wiley & Sons, Inc. (1995).
Barbas, Carlos F. et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity," 1994, Proceedings of the National Academy of Science U.S.A., vol. 91, pp. 3809-3813.
Bass, Brenda L., "The short answer," 2001, Nature, vol. 411, pp. 428-429.
Bergmann, Cornelia C. et al., "Flanking residues Alter Antigenicity and Immunogenicity of Multi-Unit CTL Epitopes," 1996, Journal of Immunology, vol. 157, pp. 3242 3249.
Bergmann, Cornelia et al., "An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein," 1993, European Journal of Immunology, vol. 23, pp. 2777-2781.
Bhasin, Shalender et al., "Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded doses of Testosterone on the Skeletal Muscle," 2005, Journal of Clinical Endocrinology & Metabolism, vol. 90, pp. 678-688.
Bhasin, Shalender et al., "Testosterone dose-response relationships in healthy young men," 2001, American Journal of Physiology Endocrinology and Metabolism, vol. 281, E1172-E1181.
Bogdanovich, Sasha et al., "Functional improvement of dystrophic muscle by myostatin blockade," 2002, Nature, vol. 420, pp. 418-421.
Brown, Peter D. et al., "Physicochemical Activation of Recombinant Latent Transforming Frowth Factor-beta's 1, 2, and 3," 1990, Growth Factors, vol. 3, pp. 35-43.
Casset et al. (Biochem Biophys Res Comm. 2003; 307:198-205). *
Chen et al. (J Mol Biol. 1999; 293:865-881). *
Clackson, Tim et al., "Making antibody fragments using phage display libraries," 1991, Nature, vol. 352, pp. 624-628.
Current Protocols in Molecular Biology, 2nd ed., Ausubel et al. eds., John Wiley & Sons, 1992.
Davis, Mindy I. et al., "Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase," 2005, Proceedings of the National Academy of Science US, vol. 102, pp. 5981-5986.
Derynck, Rik et al., "Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells," 1995, Nature, vol. 316, pp. 701-705.
Derynck, Rik et al., "Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells," 1995, Nature, vol. 316, pp. 701-705.
DNA Cloning, vols. I and II (D. N Glover ed. 1985).
Dorn, Gabriele et al., "siRNA relieves chronic neuropathic pain," 2004, Nucleic Acids Research, vol. 32, pp. e49.
Elbashir, Sayda M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," 2001, Nature, vol. 411, pp. 494-498.
Elbashir, Sayda M. et al., "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate," 2001, EMBO Journal, vol. 20, pp. 6877-6888.
Epitope Mapping Protocols in Methods in Molecular Biology, vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N. J.
Frank, Ronald, "Spot-Synthesis: An Easy Technique for the Positionally Addressable, Parallel Chemical Synthesis on a Membrane Support," 1992, Tetrahedron, vol. 48, pp. 9217-9232.
Fundamental Immunology, 3rd ed. (1993), ed. Paul, Raven Press, New York, NY.
Galderisi, Umberto et al., "Antisense Oligonucleotides as Therapeutic Agents," 1999, Journal of Cellular Physiology, vol. 181, pp. 251-257.
Gamer, Laura W. et al., "A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer in Xenopus Embryos," 1999, Developmental Biology, vol. 208, pp. 222-232.
Gardlik, Roman et al., "Vectors and delivery systems in gene therapy," 2005, Medical Science Monitor, vol. 11, pp. RA110-RA121.
Gardner et al. (1998) 12th World AIDS Conference, Geneva, Switzerland, Jun. 28 Jul. 3, 1998.
Gene Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos eds. 1987, Cold Spring Harbor Laboratory).
Gentry, Larry E. et al., "The Pro Domain of Pre-Pro-Transforming Growth Factor beta1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor," 1990 Biochemistry, vol. 29, pp. 6851-6857.
Gentry, Larry E. et al., "The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor," 1990 Biochemistry, vol. 29, pp. 6851-6857.
Geysen, H, Mario et al., "A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant," 1986, Molecular Immunology, vol. 23, pp. 709-715.
Geysen, H. Mario et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," 1984, Proceedings of the National Academy of Science USA, vol. 81, pp. 3998-4002.
Gonzalez-Cadavid, Nestor F. et al., "Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting," 1998, Proceedings of the National Academy of Science U.S.A, vol. 95, pp. 14938-14943.
Gram, Hermann et al., "In vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library," 1992, Proceedings of the National Academy of Science U.S.A., vol. 89, pp. 3576-3580.
Haffar, OK, et al., Topogenic Analysis of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, p. 160, in Microsomal Membranes, J. Cell Biol., Nov. 1, 1988, 107:1677-87.
Halpin, David R. and Harbury, Pehr B., "DNA Dsisplay II. Genetic Manipulation of Combinatorial Chemistry Libraries for Small-Molecule Evolution," 2004, PLos Biology, vol. 2, pp. 1022-1030.
Hamrick, M. W. et al., Femoral Morphology and Cross-sectional Geometry of Adult Myostatin-deficient Mice, 2000, Bone, vol. 27, pp. 343-349.
Handbook of Experimental Immunology, vols. I IV (D. M. Weir and C. C. Blackwell eds. (1986).
Heasman, Janet, "Morpholino Oligos: Making Sense of Antisense?" 2002, Developmental Biology, vol. 243, pp. 209-214.
Holm et al. (Mol Immunol. 2007; 44(6):1075-1084). *
Hoodless, P. A. and Wrana, J. L., "Mechanism and Function of Signaling by the TGFbeta Superfamily," 1998, Current Topics in Microbiology and Immunology, vol. 228, pp. 235-272.
Hoodless, P. A. and Wrana, J. L., "Mechanism and Function of Signaling by the TGFβ Superfamily," 1998, Current Topics in Microbiology and Immunology, vol. 228, pp. 235-272.
Immobilized Cells and Enzymes (IRL Press, 1986).
Immunochemical Methods in Cell and Molecular Biology (Academic Press, London), Scopes, (1987).
Immunoglobulin Genes, 2nd ed. (1995), eds. Jonio et al., Academic Press, San Diego, CA.
International Preliminary Report on Patentability (IPRP) from PCT/US2008/012338 (WO 2009/056346): date of issuance of report is May 4, 2010.
Kambadur, Ravi et al., "Mutations in myostatin (GDF8) in Double-Muscled Belgian Blue and Piedmontese Cattle," 1997, Genome Research, vol. 7, pp. 910-915.
Karp, Peter D., "An ontology for biological function based on molecular interactions," 2000, Bioinformatics Ontology, vol. 16, pp. 269-285.
Kim, H. S. et al., "Inhibition of Preadipocyte Differentiation by Myostatin Treatment in 3T3-L1 Cultures," 2000, Biochemical and Biophysical Research Communications, vol. 281, pp. 902-906.
Kingsley, David M. et al., "The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms," 1994, Genes & Development, vol. 8, pp. 133-146.
Kingsley, David M. et al., "The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms," 1994, Genes & Development, vol. 8, pp. 133-146.
Knauert, Melissa P. and Glazer, Peter M., "Triplex forming oligonucleotides: sequence-specific tools for gene targeting," 2001, Human Molecular Genetics, vol. 10, pp. 2243-2251.
Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," 1975, Nature, vol. 256, pp. 495-499.
Lee, Se-Jin and McPherron, Alexandra C., "Myostatin and the control of skeletal muscle mass," 1999, Current Opinion in Genetics & Development, vol. 9, pp. 604-607.
Lee, Se-Jin and McPherron, Alexandra C., "Regulation of myostatin activity and muscle growth," 2001, Proceedings of the National Academy of Science USA, vol. 98, pp. 9306-9311.
Lund, John et al., Human FcgammaRI and FcgammaRII Interact with Distinct but Overlapping Sites on Human IgG1, 1991, Journal of Immunology, vol. 147, pp. 2657-2662.
Lund, John et al., Human FcγRI and FcγRII Interact with Distinct but Overlapping Sites on Human IgG1, 1991, Journal of Immunology, vol. 147, pp. 2657-2662.
MacCallum et al. (J Mol Biol. 1996; 262:732-745). *
Marks, James D. et al., "By-passing Immunization Human Antibodies from V-gene Libraries displayed on Phage," 1991, Journal of Molecular Biology, vol. 222, pp. 581-597.
Marks, James D. et al., "By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"1992, Bio/Technology, vol. 10, pp. 779-783.
Massague, Joan, "The Transforming Growth Factor-beta Family," 1990, Annual Review of Cell Biology, vol. 6, pp. 597-641.
Massague, Joan, "The Transforming Growth Factor-β Family," 1990, Annual Review of Cell Biology, vol. 6, pp. 597-641.
McCroskery, Seumas et al., "Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice," 2005, Journal of Cell Science, vol. 118, pp. 3531-3541.
McCroskery, Seumas et al., "Myostatin negatively regulates satellite cell activation and self-renewal," 2003, Journal of Cell Biology, vol. 162, pp. 1135-1147.
McPherron, Alexandra C. and Lee, Se-Jin, "Double muscling in cattle due to mutations in the myostatin gene," 1997, Proceedings of the National Academy of Science U.S.A. vol. 94, pp. 12457-12461.
McPherron, Alexandra C. and Lee, Se-Jin, "Suppression of body fat accumulation in myostatin-deficient mice," 2002, Journal of Clinical Investigation, vol. 109, pp. 595-601.
McPherron, Alexandra C. et al., "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member," 1997, Nature, vol. 387, pp. 83-90.
McPherron, Alexandra C. et al., "Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member," 1997, Nature, vol. 387, pp. 83-90.
Meyers et al. ((1988) Comput. Appl. Biosci., vol. 4, pp. 11-17.
Micklefield, Jason, "Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications," 2001, Current Medicinal Chemistry, vol. 8, pp. 1157-1179.
Miyazono, Kohei et al., "Latent High Molecular Weight Complex of Transforming Growth Factor beta1 Purification From Human Platelets and Structural Characterization," 1988, Journal of Biological Chemistry, vol. 263, pp. 6407-6415.
Miyazono, Kohei et al., "Latent High Molecular Weight Complex of Transforming Growth Factor β1 Purification From Human Platelets and Structural Characterization," 1988, Journal of Biological Chemistry, vol. 263, pp. 6407-6415.
Molina, F. et al., "Improved Performances of Spot Multiple Peptide Synthesis," 1996, Peptide Research, vol. 9, pp. 151-155.
Morgan, A. et al., "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcgammaRI and FcgammaRIII binding," 1995, Immunology, vol. 86, pp. 319-324.
Morgan, A. et al., "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding," 1995, Immunology, vol. 86, pp. 319-324.
Needleman, Saul B. and Wunsch, Christan D., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," 1970, Journal of Molecular Biology, vol. 48, pp. 444-453.
Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984).
Oligonucleotide Synthesis (M. J. Gait ed., 1984).
Paddison, Patrick J. et al., "Stable suppression of gene expression by RNAi in mammalian cells," 2002, Proceedings of the National Academy of Science USA, vol. 99, pp. 1443-1448.
Paul, Fundamental Immunology, 1993, pp. 292-295, under the heading Fv Structure and Diversity in Three Dimensions. *
PCT/US2008/012338 International Search Report mailed Mar. 3, 2009.
Pedley, R. B. et al., "The potential for enhanced tumour localization by poly(ethylene glycol) modification of anti-CEA antibody," 1994, British Journal of Cancer, vol. 70, pp. 1126-1130.
Rebbapragada, A. et al., "Myostatin Signals through a Transforming Growth Factor beta-Like Signaling Pathway to Block Adipogenesis," 2003, Molecular and Cellular Biology, vol. 23, pp. 7230-7242.
Rebbapragada, A. et al., "Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway to Block Adipogenesis," 2003, Molecular and Cellular Biology, vol. 23, pp. 7230-7242.
Reynolds, Angela et al., "Rational siRNA design for RNA interference," 2004, Nature Biotechnology, vol. 22, pp. 326-330.
Sambrook et al., Molecular Cloning: A Laboratory Manual, Chs. 9 & 11, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989).
Sambrook, et al., Molecular Cloning: A Laboratory Manual: Second Edition, Cold Spring Harbor Laboratory Press, 1989.
Schier, Robert et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," 1996, Journal of Molecular Biology, vol. 263, pp. 551-567.
Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991), eds. Kabat et al.
Sinha-Hikim, Indrani et al., "The Use of a Sensitive Equilibrium Dialysis Method for the Measurement of Free Testosterone Levels in Healthy, Cycling Women and in Human Immunodeficiency Virus-Infected Women," 1998, Journal of Clinical Endocrinology and Metabolism, vol. 83, pp. 1312-1318.
Sioud, Mouldy, "Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents," 2001, Current Molecular Medicine, vol. 1, pp. 575-588.
Stemmer, Willem P. C., "Rapid evolution of a protein in vitro by DNA shuffling," 1994, Nature, vol. 370, pp. 389-391.
Storer, Thomas W. et al., "Testosterone Dose-Dependently Increases Maximal Voluntary Strength and Leg Power, but Does Not Affect Fatigability or Specific Tension," 2003, Journal of Clinical Endocrinology Metabolism, vol. 88, pp. 1478-1485.
Suhrbier, A., "Multi-epitope DNA vaccines," 1997, Immunology and Cell Biology, vol. 75, pp. 402 408.
Sui, Guangchao et al., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, 2002, Proceedings of the National Academy of Science USA, vol. 99, pp. 5515-5520.
Swatland, H. J. et al., "Fetal Development of the Double Muscled Condition in Cattle," 1974, Journal of Animal Science, vol. 38, pp. 752-757.
Thies, R. Scott et al., "GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding," 2001, Growth Factors, vol. 18, pp. 251-259.
Thomas, Mark et al., "Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation," 2000, Journal of Biological Chemistry, vol. 275, pp. 40235-40243.
Transcription and Translation (B. D. Hames & S. J. Higgins eds. 1984).
Vajdos et al. (J Mol Biol. 2002; 320(2):415-428). *
Verkman, A. S., "Drug discovery in academia," 2004, AJP-Cell Physiol,. vol. 286, pp. 465-474.
Voet and Voet, Biochemistry, 2nd ed., ed. N. Rose, Wiley and Sons, New York, 14 (1995).
Wagner, Kathryn R. et al., "Loss of Myostatin Attenuates Severity of Muscular Dystrophy in mdx Mice," 2002, Ann. Neurol., vol. 52, pp. 832-836.
Wagner, KR, et al., A Phase I/II Trial of MYO-029 in Adult Subjects With Muscular Dystrophy, Ann. Neurol., May 2008, 63:561-71.
Wakefield, Lalage M. et al., "Latent Transforming Growth Factor-beta from Human Platelets A High Molecular Weight Complex Containing Precursor Sequence," 1988, Journal of Biological Chemistry, vol. 263, pp. 7646-7654.
Wakefield, Lalage M. et al., "Latent Transforming Growth Factor-β from Human Platelets A High Molecular Weight Complex Containing Precursor Sequence," 1988, Journal of Biological Chemistry, vol. 263, pp. 7646-7654.
Whittemore, Lisa-Anne et al., "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength," 2003, Biochemical and Biophysical Research Communications, vol. 300, pp. 965-971.
Yu, Jenn-Yah et al., RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells, 2002, Proceedings of the National Academy of Science USA, vol. 99, pp. 6047-6052.
Zimmers, Teresa A. et al., "Induction of Cachexia in Mice by Systemically Administered Myostatin," 2002, Science, vol. 296, pp. 1486-1488.

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US10189896B2 (en) * 2007-11-01 2019-01-29 Pfizer Inc. Antibody to GDF8 and uses thereof
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11655291B2 (en) 2011-11-14 2023-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10597443B2 (en) 2013-05-06 2020-03-24 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9758576B2 (en) 2013-05-06 2017-09-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11827698B2 (en) 2013-05-06 2023-11-28 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10981981B2 (en) 2013-05-06 2021-04-20 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US10934349B2 (en) 2015-04-15 2021-03-02 Regeneron Pharmaceuticals, Inc. Methods for increasing lean body mass with resistance training and a GDF8 inhibitor that is an anti-GDF8 antibody
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
US20220275076A1 (en) * 2015-12-25 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP4169942A1 (en) 2016-03-11 2023-04-26 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017221145A1 (en) 2016-06-21 2017-12-28 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
US11248044B2 (en) 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
WO2019169283A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
EP3677278A1 (en) 2018-07-11 2020-07-08 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
EP4019046A1 (en) 2018-07-11 2022-06-29 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
WO2020261178A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof

Also Published As

Publication number Publication date
JP2011504096A (ja) 2011-02-03
JP5756291B2 (ja) 2015-07-29
ZA201003876B (en) 2011-04-28
PE20091163A1 (es) 2009-08-09
US9409981B2 (en) 2016-08-09
KR20100074321A (ko) 2010-07-01
CA2704315A1 (en) 2009-05-07
CA2704315C (en) 2016-05-24
EP2215118B1 (en) 2014-08-06
CN101970487A (zh) 2011-02-09
TW200934510A (en) 2009-08-16
US9850301B2 (en) 2017-12-26
US20090148436A1 (en) 2009-06-11
CO6270358A2 (es) 2011-04-20
EP2215118A1 (en) 2010-08-11
EP2805970A3 (en) 2015-03-04
MX2010004915A (es) 2010-05-27
RU2447084C2 (ru) 2012-04-10
SA08290697B1 (ar) 2012-02-12
US20170145084A1 (en) 2017-05-25
AR069157A1 (es) 2009-12-30
US20180265578A1 (en) 2018-09-20
ES2514518T3 (es) 2014-10-28
US20140023638A1 (en) 2014-01-23
AU2008319265A1 (en) 2009-05-07
IL205448A0 (en) 2010-12-30
EP2805970A2 (en) 2014-11-26
WO2009058346A1 (en) 2009-05-07
US10189896B2 (en) 2019-01-29
RU2010117018A (ru) 2011-12-10
PA8802601A1 (es) 2009-06-23

Similar Documents

Publication Publication Date Title
US10189896B2 (en) Antibody to GDF8 and uses thereof
US9926368B2 (en) Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8
CA2722600C (en) Anti-hepcidin antibodies and methods of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAVALLIE, EDWARD ROLAND;COLLINS-RACIE, LISA ANNE;CORCORAN, CHRISTOPHER JOHN;AND OTHERS;REEL/FRAME:022125/0101;SIGNING DATES FROM 20081208 TO 20090114

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAVALLIE, EDWARD ROLAND;COLLINS-RACIE, LISA ANNE;CORCORAN, CHRISTOPHER JOHN;AND OTHERS;SIGNING DATES FROM 20081208 TO 20090114;REEL/FRAME:022125/0101

AS Assignment

Owner name: WYETH LLC,NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:WYETH;REEL/FRAME:024541/0922

Effective date: 20091109

Owner name: WYETH LLC, NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:WYETH;REEL/FRAME:024541/0922

Effective date: 20091109

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210409